• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hierarchy of mono- and biallelic alterations in multiple myeloma cell fitness.

作者信息

Munawar Umair, Rasche Leo, Müller Nicole, Vogt Cornelia, Da-Via Matteo, Haertle Larissa, Arampatzi Panagiota, Dietrich Sascha, Roth Markus, Garitano-Trojaola Andoni, Steinhardt Maximilian Johannes, Strifler Susanne, Gallardo Miguel, Martinez-Lopez Joaquin, Bargou Ralf C, Heckel Tobias, Einsele Hermann, Stühmer Thorsten, Kortüm K Martin, Barrio Santiago

机构信息

Comprehensive Cancer Center Mainfranken.

Division of Hematology and Oncology, Department of Internal Medicine II, and.

出版信息

Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24.

DOI:10.1182/blood.2019000080
PMID:31340981
Abstract
摘要

相似文献

1
Hierarchy of mono- and biallelic alterations in multiple myeloma cell fitness.多发性骨髓瘤细胞适应性中单个等位基因和双等位基因改变的层级关系。
Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24.
2
Subclonal copy number is associated with prognosis in multiple myeloma.亚克隆拷贝数与多发性骨髓瘤的预后相关。
Blood. 2018 Dec 6;132(23):2465-2469. doi: 10.1182/blood-2018-06-857250. Epub 2018 Oct 29.
3
Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma.多发性骨髓瘤的失调预后、生物学和靶向治疗。
Cells. 2020 Jan 24;9(2):287. doi: 10.3390/cells9020287.
4
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.克隆选择以及涉及肿瘤抑制基因的双打击事件是骨髓瘤复发的基础。
Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.
5
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.采用基因相同细胞系模型评估多发性骨髓瘤中 TP53 损伤对 p53 系统功能和耐药性的影响。
Sci Rep. 2019 Dec 2;9(1):18062. doi: 10.1038/s41598-019-54407-4.
6
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.高亚克隆 17p 缺失分数与多发性骨髓瘤的不良预后相关。
Blood. 2019 Mar 14;133(11):1217-1221. doi: 10.1182/blood-2018-10-880831. Epub 2019 Jan 28.
7
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.多发性骨髓瘤中TP53缺失的临床和生物学意义分析以及TP53潜在新转录靶点的鉴定。
Blood. 2008 Nov 15;112(10):4235-46. doi: 10.1182/blood-2007-10-119123. Epub 2008 Mar 12.
8
Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.免疫组织化学检测到的异常核p53蛋白表达与多发性骨髓瘤的P53半合子缺失及较差的生存率相关。
Br J Haematol. 2007 Aug;138(3):324-9. doi: 10.1111/j.1365-2141.2007.06649.x. Epub 2007 Jun 7.
9
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.自体造血干细胞移植后伴有TP53缺失的多发性骨髓瘤患者的预后
Am J Hematol. 2016 Oct;91(10):E442-7. doi: 10.1002/ajh.24487. Epub 2016 Sep 3.
10
Clonal competition with alternating dominance in multiple myeloma.多发性骨髓瘤中具有交替优势的克隆竞争。
Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.

引用本文的文献

1
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.利用基因组学鉴定多发性骨髓瘤高危亚组中的新型免疫治疗靶点。
Genome Med. 2025 Jul 15;17(1):79. doi: 10.1186/s13073-025-01503-y.
2
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.克隆竞争分析确定了多发性骨髓瘤进展和耐药中的适应性特征。
Hemasphere. 2024 Jul 11;8(7):e110. doi: 10.1002/hem3.110. eCollection 2024 Jul.
3
Molecular and immunological mechanisms of clonal evolution in multiple myeloma.
多发性骨髓瘤克隆进化的分子和免疫学机制。
Front Immunol. 2023 Sep 6;14:1243997. doi: 10.3389/fimmu.2023.1243997. eCollection 2023.
4
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.通过多组学亚克隆分析解决多发性骨髓瘤的治疗抵抗机制。
Blood. 2023 Nov 9;142(19):1633-1646. doi: 10.1182/blood.2023019758.
5
Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells.p53 缺失增强了克隆性多发性骨髓瘤细胞的肿瘤起始能力和耐药性。
Blood Adv. 2023 Jul 25;7(14):3551-3560. doi: 10.1182/bloodadvances.2022009387.
6
Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations.多发性骨髓瘤的细胞遗传学异常：印度和西方人群中的发病率、预后意义及地理异质性
Cytogenet Genome Res. 2022;162(10):529-540. doi: 10.1159/000529191. Epub 2023 Feb 13.
7
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase () Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma.基于多发性骨髓瘤中蛋白酶体抑制剂耐药性对蛋白酶体26S亚基AAA-ATP酶（）基因家族成员的基因改变
Cancers (Basel). 2023 Jan 15;15(2):532. doi: 10.3390/cancers15020532.
8
Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma.基因组复杂性对多发性骨髓瘤转录组的功能影响。
Clin Cancer Res. 2021 Dec 1;27(23):6479-6490. doi: 10.1158/1078-0432.CCR-20-4366. Epub 2021 Sep 15.
9
Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma.多发性骨髓瘤的失调预后、生物学和靶向治疗。
Cells. 2020 Jan 24;9(2):287. doi: 10.3390/cells9020287.